Clinical trials: Schizophrenic Disorders
Schizophrenia
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
- Trial name
- NCT00694707
- Testing
- Cariprazine, Risperidone
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 732 people
- Sponsor
- Forest Laboratories
Healthy
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers
- Trial name
- NCT02228395
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Schizophrenia
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.
- Trial name
- NCT01614912
- Testing
- SM-13496
- Where
- 4 sites in Japan, Malaysia and 2 more
- Volunteers
- 284 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.
- Trial name
- NCT01854944
- Testing
- Brexpiprazole 1mg to 4mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Impulsive Behavior
Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally…
- Trial name
- NCT03838484
- Testing
- Nicotine Patch, 7 Mg/24 Hr
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Psychotic Disorders
Facilitating Engagement in Evidence-Based Treatment for Early Psychosis
The purpose of this mixed methods study is to evaluate a peer-delivered decision support intervention with emerging adults newly enrolled in an early intervention program, also known as coordinated specialty care (CSC).
- Trial name
- NCT04532034
- Testing
- Peer-Delivered Decision Support Intervention
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Temple University
Schizophrenia
Benefits of Physical Exercise in Schizophrenia
Impairments in social integration, characterized by low marriage rates, few friendships, and a high frequency of living alone, affect the vast majority of Veterans with schizophrenia.
- Trial name
- NCT02716584
- Testing
- Physical exercise, Stretching exercise
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- VA Office of Research and Development
Schizoaffective Disorder, Schizophrenia
Smoking Cessation for Veterans With Severe and Persistent Mental Illness
The investigators have developed an intervention called Behavioral Treatment of Smoking Cessation in SPMI (BTSCS), an innovative intervention that supplements pharmacotherapy and education with contingency management and a…
- Conditions
- Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
- Trial name
- NCT00960375
- Testing
- BTSCS, StSST
- Where
- 2 sites in United States
- Volunteers
- 179 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Tryptophan MRI in People With Schizophrenia and Healthy Controls
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine.
- Trial name
- NCT02067975
- Testing
- Tryptophan
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia
- Trial name
- NCT00257192
- Testing
- Ziprasidone oral capsules
- Where
- 92 sites in United States, Colombia and 7 more
- Volunteers
- 284 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg
To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.
- Trial name
- DWCZP-I-1 (NCT01654601)
- Testing
- DWCZP, Clozaril
- Where
- 5 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Schizophrenia, Schizoaffective Disorder
Biomarkers in Schizophrenia
N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia.
- Trial name
- NCT00817336
- Testing
- D Serine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Implementing mHealth for Schizophrenia in Community Mental Health Settings
Randomized control trial examining two mHealth intervention strategies.
- Trial name
- NCT04147897
- Testing
- FOCUS
- Where
- 8 sites in United States
- Volunteers
- 299 people
- Sponsor
- University of Washington
Schizophrenia
Patient-Centered Medication Adherence Intervention for Schizophrenia
Efficacious antipsychotic medication treatments for schizophrenia are available; however , antipsychotic regimens frequently do not achieve their potential because of poor medication adherence.
- Trial name
- AMAIS (NCT00144027)
- Testing
- Antipsychotic medication adherence intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- US Department of Veterans Affairs
Cognitive Impairment Associated With Schizophrenia
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
- Trial name
- TALLY (NCT03745820)
- Testing
- BIIB104
- Where
- 60 sites in United States, Germany and 3 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia
Cognitive dysfunction is a major contributor to the poor community outcome of individuals with schizophrenia. Developing more effective cognitive remediation interventions is imperative to improve the daily lives of affected…
- Trial name
- NCT01891721
- Testing
- Brain Fitness Program (BFP), Cognitive Package (Cogpack), Commercial Computer Games (Sporcle)
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
- Trial name
- NCT00589914
- Testing
- RISPERDAL CONSTA, Paliperidone palmitate
- Where
- 82 sites in United States, Austria and 12 more
- Volunteers
- 1,221 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.